Gene editing for heart disease: Verve kicks off landmark base editing trial
Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major milestone for the next-gen gene editing technique known as base editing.
Now officially in a Phase Ib clinical trial in New Zealand, VERVE-101 is a single base editor designed to permanently turn off the PCSK9 gene in patients with heterozygous familial hypercholesterolemia, who have dangerously high cholesterol levels.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.